Liquidia: Yutrepia Has Impressed, But Here's Why I Remain Cautious (Rating Upgrade)
Source: SeekingAlpha
2026-03-26 07:30:42 ET
Overview
Liquidia's stock ( LQDA ) is up a solid 16% since my " Sell " rating to begin the year. Its commercialization of Yutrepia (treprostinil powder) has gone quite well....
Read the full article on Seeking Alpha
For further details see:
Liquidia: Yutrepia Has Impressed, But Here's Why I Remain Cautious (Rating Upgrade)
Liquidia Corporation
NASDAQ: LQDA
LQDA Trading
21.73% G/L:
$66.17 Last:
2,617,784 Volume:
$55.14 Open:
LQDA Latest News
May 27, 2026 08:30:00 am
Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference
May 13, 2026 12:43:57 pm
What to Know About This Fund's $15.5 Million Sale of Liquidia as Shares Skyrocket Nearly 260%
LQDA Stock Data
$3,502,438,146
63,941,680
1.04%
70
N/A
Biotechnology & Life Sciences
Healthcare
US
Morrisville
